Evidence map›Paper›PMID 38542506›Full record

ArticleInternational journal of molecular sciences2024

Comparative Analyses of Targeted Myeloid Cancer Next-Generation Sequencing Panel in Fresh Blood, Bone Marrow and FFPE Material.

Andrea Daniela Hobeck, Sophia Wendt, Saskia Krohn, Gudrun Knuebel, Stephan Bartels, Elisa Schipper, Christian Junghanss, Hugo Murua Escobar

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Andrea Daniela HobeckClinic for Hematology, Oncology and Palliative Care, Medical Clinic III, Department of Internal Medicine, Rostock University Medical Center, Ernst-Heydemann-Strasse 6, 18057 Rostock, Germany.
Sophia WendtClinic for Hematology, Oncology and Palliative Care, Medical Clinic III, Department of Internal Medicine, Rostock University Medical Center, Ernst-Heydemann-Strasse 6, 18057 Rostock, Germany.
Saskia KrohnClinic for Hematology, Oncology and Palliative Care, Medical Clinic III, Department of Internal Medicine, Rostock University Medical Center, Ernst-Heydemann-Strasse 6, 18057 Rostock, Germany.
Gudrun KnuebelClinic for Hematology, Oncology and Palliative Care, Medical Clinic III, Department of Internal Medicine, Rostock University Medical Center, Ernst-Heydemann-Strasse 6, 18057 Rostock, Germany.
Stephan BartelsInstitute of Pathology, Department of Molecular Pathology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany.
Elisa SchipperInstitute of Pathology, Department of Molecular Pathology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany.
Christian JunghanssClinic for Hematology, Oncology and Palliative Care, Medical Clinic III, Department of Internal Medicine, Rostock University Medical Center, Ernst-Heydemann-Strasse 6, 18057 Rostock, Germany.
Hugo Murua EscobarClinic for Hematology, Oncology and Palliative Care, Medical Clinic III, Department of Internal Medicine, Rostock University Medical Center, Ernst-Heydemann-Strasse 6, 18057 Rostock, Germany.ORCID 0000-0001-7123-7986

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Next-generation sequencing is a vital tool for personalized diagnostics and therapies in cancer. Despite numerous advantages, the method depends on multiple parameters regarding the sample material, e.g., sample fixation. A panel's ability to ensure balanced pre-amplification of the regions of interest is challenging, especially in targeted sequencing approaches, but of significant importance to its applicability across hematological malignancies and solid tumors. This study comparatively evaluated the technical performance of the commercially available Oncomine

Indexed as

Myeloproliferative DisordersNeoplasmsBone MarrowFormaldehydeHigh-Throughput Nucleotide SequencingHumansMutationParaffin EmbeddingTissue FixationFormaldehydeamplicon sequencing performanceFFPE materialfresh blood/bone marrow materialnext-generation sequencingOncomineTM Myeloid Panel

Identifiers

PMID38542506
PMCPMC10970853

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.